CCNC

Cyclin-C

53,070 patent compounds predicted against CCNC, 24,621 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL578403	0.67	16/20
SCHEMBL578754	0.52	16/20
SCHEMBL1006232	0.64	15/20
SCHEMBL1006234	0.64	15/20
SCHEMBL578607	0.59	14/20
SCHEMBL348179	0.54	14/20
SCHEMBL578764	0.56	13/20
SCHEMBL578632	0.54	13/20
SCHEMBL660279	0.63	10/20
SCHEMBL743165	0.45	10/20
SCHEMBL1019077	0.64	9/20
SCHEMBL578414	0.60	9/20
SCHEMBL1006747	0.44	9/20
SCHEMBL253500	0.40	9/20
Trifluoroacetic Acid (SCHEMBL1020377)	0.57	8/20
SCHEMBL578476	0.49	8/20
SCHEMBL717713	0.51	7/20
SCHEMBL966355	0.46	7/20
SCHEMBL966357	0.46	7/20
SCHEMBL1034211	0.56	6/20

Germline variants in CCNC on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full CCNC gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to CCNC by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, HR+ and HER2- Breast Cancer	PHASE4	NOT_YET_RECRUITING
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)	PHASE3	COMPLETED
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer	PHASE2	WITHDRAWN
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas	PHASE2	RECRUITING
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)	PHASE1/PHASE2	RECRUITING
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	PHASE2	COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6	PHASE2	RECRUITING
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma	PHASE1/PHASE2	RECRUITING
Palbociclib and Pembrolizumab In Central Nervous System Metastases	PHASE2	RECRUITING
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression	PHASE2	COMPLETED
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.	PHASE1/PHASE2	COMPLETED
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer	PHASE2	RECRUITING
BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors	PHASE2	WITHDRAWN
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors	PHASE1/PHASE2	COMPLETED
Study of FCN-437c in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer	PHASE1	ACTIVE_NOT_RECRUITING
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma	PHASE1	COMPLETED
Erlotinib in Treating Patients With Barrett Esophagus	PHASE1	UNKNOWN
Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors	PHASE1	COMPLETED
Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA	PHASE1	RECRUITING
Tucatinib + Abemaciclib + Herceptin for HER2+ MBC	PHASE1	WITHDRAWN
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer	nan	COMPLETED
The Use of Immunohistochemical Staining for the Prediction of Wilms Tumour Progression and Recurrence	nan	UNKNOWN
Study of Tissue and Blood Samples From Patients With Low-Grade Glioma	nan	COMPLETED
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period	nan	UNKNOWN
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CCNC binder may also engage these)

Protein	Name	Similarity
Q3ZCK5	—	1.000	Q3ZCK5 →
Q62447	—	1.000	Q62447 →
Q4KLA0	—	1.000	Q4KLA0 →
Q28F72	—	1.000	Q28F72 →
P55168	—	1.000	P55168 →
P39947	—	0.984	P39947 →
Q5R532	—	0.926	Q5R532 →
Q5F398	—	0.925	Q5F398 →
COPS2	COP9 signalosome complex subunit 2	0.923	landscape →
Q4R9A8	—	0.921	Q4R9A8 →
Q4VC33	—	0.921	Q4VC33 →
Q5R8K2	—	0.921	Q5R8K2 →
Q99LC2	—	0.920	Q99LC2 →
Q5BJQ6	—	0.920	Q5BJQ6 →
Q7SXR3	—	0.919	Q7SXR3 →
P61203	—	0.919	P61203 →
Q05048	—	0.919	Q05048 →
Q32NS4	—	0.918	Q32NS4 →
Q6IQT4	—	0.918	Q6IQT4 →
Q7L5Y9	—	0.918	Q7L5Y9 →
Q3UHD6	—	0.917	Q3UHD6 →
Q6IR75	—	0.917	Q6IR75 →
B1H1E4	—	0.917	B1H1E4 →
A5PKA5	—	0.917	A5PKA5 →
Q9UL63	—	0.917	Q9UL63 →
P61202	—	0.917	P61202 →
Q6GR10	—	0.916	Q6GR10 →
Q9UKF6	—	0.915	Q9UKF6 →
O89050	—	0.915	O89050 →
Q6PFJ9	—	0.915	Q6PFJ9 →